Oxidative Stress in Parkinson's Disease

Parkinson's disease (PD) is a common adult‐onset neurodegenerative disorder. Typically PD is a sporadic neurological disorder, and over time affected patients see their disability growing and their quality of life declining. Oxidative stress has been hypothesized to be linked to both the initiation and the progression of PD. Preclinical findings from both in vitro and in vivo experimental models of PD suggest that the neurodegenerative process starts with otherwise healthy neurons being hit by some etiological factors, which sets into motion a cascade of deleterious events. In these models initial molecular alterations in degenerating dopaminergic neurons include increased formation of reactive oxygen species, presumably originating from both inside and outside the mitochondria. In the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of PD, time‐course experiments suggest that oxidative stress is an early event that may directly kill some of the dopaminergic neurons. In this model it seems that oxidative stress may play a greater role in the demise of dopaminergic neurons indirectly by activating intracellular, cell death‐related, molecular pathways. As the neurodegenerative process evolves in the MPTP mouse model, indices of neuroinflammation develop, such as microglial activation. The latter increases the level of oxidative stress to which the neighboring compromised neurons are subjected to, thereby promoting their demise. However, these experimental studies have also shown that oxidative stress is not the sole deleterious factor implicated in the death of dopaminergic neurons. Should a similar multifactorial cascade underlie dopaminergic neuron degeneration in PD, then the optimal therapy for this disease may have to rely on a cocktail of agents, each targeting a different critical component of this hypothesized pathogenic cascade. If correct, this may be a reason why neuroprotective trials using a single agent, such as an antioxidant, have thus far generated disappointing results.

[1]  C. Marsden,et al.  α‐tocopherol levels in brain are not altered in Parkinson's disease , 1992 .

[2]  C. Shults Lewy bodies. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Min Zhu,et al.  Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles. , 2006, Biochemistry.

[4]  Pasko Rakic,et al.  JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  E. Hirsch,et al.  The Role of Glial Reaction and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.

[6]  J. Trojanowski,et al.  Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. , 2005, Biochemistry.

[7]  J. Trojanowski,et al.  Reversible Inhibition of α-Synuclein Fibrillization by Dopaminochrome-mediated Conformational Alterations* , 2005, Journal of Biological Chemistry.

[8]  Michael Zuker,et al.  Mfold web server for nucleic acid folding and hybridization prediction , 2003, Nucleic Acids Res..

[9]  Makoto Hashimoto,et al.  Transgenic Models of α‐Synuclein Pathology , 2003 .

[10]  M. Beal,et al.  Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients , 1998, Neurology.

[11]  M. Vila,et al.  Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Fortini Faculty Opinions recommendation of Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. , 2003 .

[13]  Xiongwei Zhu,et al.  Mitochondrial failures in Alzheimer's disease , 2004, American journal of Alzheimer's disease and other dementias.

[14]  T. Dawson,et al.  DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase , 2007, Proceedings of the National Academy of Sciences.

[15]  D. Ben-shachar,et al.  Iron, melanin and dopamine interaction: relevance to parkinson's disease , 1993, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[16]  J. Trojanowski,et al.  More than just two peas in a pod: common amyloidogenic properties of tau and α-synuclein in neurodegenerative diseases , 2004, Trends in Neurosciences.

[17]  T. Rouault Post-transcriptional regulation of human iron metabolism by iron regulatory proteins. , 2002, Blood cells, molecules & diseases.

[18]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[19]  C. Moraes,et al.  Titrating the Effects of Mitochondrial Complex I Impairment in the Cell Physiology* , 1999, The Journal of Biological Chemistry.

[20]  T. Hastings Enzymatic Oxidation of Dopamine: The Role of Prostaglandin H Synthase , 1995, Journal of neurochemistry.

[21]  B. Westerink,et al.  Brain dialysis in conscious rats reveals an instantaneous massive release of striatal dopamine in response to MPP+. , 1986, European journal of pharmacology.

[22]  G. Perry,et al.  Metal ions and oxidative protein modification in neurological disease. , 2005, Annali dell'Istituto superiore di sanita.

[23]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Trojanowski,et al.  Parkinson's Disease and Related α‐Synucleinopathies Are Brain Amyloidoses , 2003, Annals of the New York Academy of Sciences.

[25]  S. Pennathur,et al.  Mass Spectrometric Quantification of 3-Nitrotyrosine, ortho-Tyrosine, and o,o′-Dityrosine in Brain Tissue of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Mice, a Model of Oxidative Stress in Parkinson's Disease* , 1999, The Journal of Biological Chemistry.

[26]  Tony Wyss-Coray,et al.  Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.

[27]  Y. Agid,et al.  Nitric oxide synthase and neuronal vulnerability in parkinson's disease , 1996, Neuroscience.

[28]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[29]  E. Floor,et al.  Increased Protein Oxidation in Human Substantia Nigra Pars Compacta in Comparison with Basal Ganglia and Prefrontal Cortex Measured with an Improved Dinitrophenylhydrazine Assay , 1998, Journal of neurochemistry.

[30]  R. Marttila,et al.  Oxygen toxicity protecting enzymes in Parkinson's disease Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus , 1988, Journal of the Neurological Sciences.

[31]  R. Palmiter,et al.  Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity , 2005, BMC Neuroscience.

[32]  T. Niki,et al.  DJ‐1 has a role in antioxidative stress to prevent cell death , 2004, EMBO reports.

[33]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[34]  S. Mandel,et al.  Early and Late Gene Changes in MPTP Mice Model of Parkinson's Disease Employing cDNA Microarray , 2002, Neurochemical Research.

[35]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[36]  M. Youdim Brain monoamine oxidase (MAO) B: A unique neurotoxin and neurotransmitter producing enzyme , 1989, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[37]  B. Halliwell Oxygen radicals: a commonsense look at their nature and medical importance. , 1984, Medical biology.

[38]  M. Elstner,et al.  Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions , 2008, Journal of Neurology.

[39]  M. Beal,et al.  Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects , 1997, Annals of neurology.

[40]  J. Mills,et al.  Asynchronous Death as a Characteristic Feature of Apoptosis , 1999 .

[41]  S. Lindquist,et al.  α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.

[42]  Manisha Patel,et al.  Iron‐sulfur enzyme mediated mitochondrial superoxide toxicity in experimental Parkinson's disease , 2004, Journal of neurochemistry.

[43]  G. Perry,et al.  Sequestration of iron by Lewy bodies in Parkinson’s disease , 2000, Acta Neuropathologica.

[44]  L. Tremblay,et al.  Experimental Models of Parkinson’s Disease , 2002, Annales pharmaceutiques francaises.

[45]  T. Mak,et al.  DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2 , 2006, Proceedings of the National Academy of Sciences.

[46]  M. Youdim Deficiency and excess of iron in brain function and dysfunction. , 2009, Nutrition reviews.

[47]  D. Selkoe,et al.  Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.

[48]  R. Palmiter,et al.  Dopamine Depletion Does Not Protect against Acute 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Toxicity In Vivo , 2005, The Journal of Neuroscience.

[49]  J. Trojanowski,et al.  Cleavage of α-Synuclein by Calpain: Potential Role in Degradation of Fibrillized and Nitrated Species of α-Synuclein† , 2005 .

[50]  A. Fink The Aggregation and Fibrillation of α-Synuclein , 2006 .

[51]  G. Kreutzberg Microglia: a sensor for pathological events in the CNS , 1996, Trends in Neurosciences.

[52]  Li Qian,et al.  Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila , 2006, Proceedings of the National Academy of Sciences.

[53]  A. Schapira Mitochondria in the aetiology and pathogenesis of Parkinson's disease , 2008, The Lancet Neurology.

[54]  M. Selley (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. , 1998, Free radical biology & medicine.

[55]  S. Korsmeyer,et al.  Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[56]  N. Hattori,et al.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[57]  T. Rouault,et al.  Brain iron metabolism. , 2006, Seminars in pediatric neurology.

[58]  Kexiang Xu,et al.  Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging , 2006, Proceedings of the National Academy of Sciences.

[59]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[60]  C. Marsden,et al.  Mitochondrial function in Parkinson's disease , 1992, Annals of neurology.

[61]  Konstantin Khrapko,et al.  Recombination of Human Mitochondrial DNA , 2004, Science.

[62]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[63]  Sid Gilman,et al.  Widespread Alterations of α-Synuclein in Multiple System Atrophy , 1999 .

[64]  K. Jellinger,et al.  Iron‐Melanin Complex in Substantia Nigra of Parkinsonian Brains: An X‐Ray Microanalysis , 1992, Journal of neurochemistry.

[65]  K. Ohno,et al.  Distinct clustering of point mutations in mitochondrial DNA among patients with mitochondrial encephalomyopathies and with Parkinson's disease. , 1991, Biochemical and biophysical research communications.

[66]  K. Jellinger,et al.  Mitochondrial DNA in Postmortem Brain from Patients with Parkinson's Disease , 1991, Journal of neurochemistry.

[67]  J. Schulz,et al.  Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease , 2007, Proceedings of the National Academy of Sciences.

[68]  E. Hirsch,et al.  Animal models of Parkinson's disease in rodents induced by toxins: an update. , 2003, Journal of neural transmission. Supplementum.

[69]  L. Thal,et al.  Characterization of the human α-synuclein gene: Genomic structure, transcription start site, promoter region and polymorphisms 1 , 2001 .

[70]  B. Halliwell,et al.  Oxygen toxicity, oxygen radicals, transition metals and disease. , 1984, The Biochemical journal.

[71]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[72]  Takeshi Iwatsubo,et al.  Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia , 1998, Cell Death and Differentiation.

[73]  R D Klausner,et al.  A cis-acting element is necessary and sufficient for translational regulation of human ferritin expression in response to iron. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[74]  R. Klausner,et al.  Regulating the fate of mRNA: The control of cellular iron metabolism , 1993, Cell.

[75]  Claudia M Testa,et al.  Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. , 2005, Brain research. Molecular brain research.

[76]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[77]  K. Okamoto,et al.  Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease , 2004, Journal of the Neurological Sciences.

[78]  Todd B. Sherer,et al.  Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.

[79]  M. Youdim,et al.  A model of MPTP-induced Parkinson's disease in the goldfish , 2007, Nature Protocols.

[80]  K. Jellinger,et al.  Neuropathological spectrum of synucleinopathies , 2003, Movement disorders : official journal of the Movement Disorder Society.

[81]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[82]  C. Ferrarese,et al.  Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: Negative correlation with levodopa dosage , 2006, Neurobiology of Disease.

[83]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[84]  C D Marsden,et al.  Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra , 1997, Journal of neurochemistry.

[85]  S. Przedborski Neuroinflammation and Parkinson's disease. , 2007, Handbook of clinical neurology.

[86]  H. M. Swartz,et al.  Interaction of neuromelanin and iron in substantia nigra and other areas of human brain , 1996, Neuroscience.

[87]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[88]  T. Montine,et al.  Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. , 1999, The American journal of pathology.

[89]  G. Perry,et al.  Biochemistry of Neurodegeneration , 2001, Science.

[90]  A. Eklund,et al.  GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein , 2008, Proceedings of the National Academy of Sciences.

[91]  E. Hirsch,et al.  How to judge animal models of Parkinson's disease in terms of neuroprotection. , 2006, Journal of neural transmission. Supplementum.

[92]  T. Joh,et al.  Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease , 2006, Experimental & Molecular Medicine.

[93]  R. Palmiter,et al.  Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic , 1995, Cell.

[94]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[95]  M. Beal,et al.  Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice , 1998, Brain Research.

[96]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[97]  Kim J. Krishnan,et al.  Age related mitochondrial degenerative disorders in humans , 2008, Biotechnology journal.

[98]  M. Vila,et al.  NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[99]  A. Nunomura,et al.  Neuronal RNA oxidation is a prominent feature of dementia with Lewy bodies , 2002, Neuroreport.

[100]  J. Trojanowski,et al.  Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro * , 1999, The Journal of Biological Chemistry.

[101]  B. Ames,et al.  Assays for 8-hydroxy-2'-deoxyguanosine: a biomarker of in vivo oxidative DNA damage. , 1991, Free radical biology & medicine.

[102]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[103]  M. Beal Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.

[104]  C. Marsden,et al.  A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.

[105]  Sarah J Tabrizi,et al.  Models of Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[106]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[107]  S. Przedborski,et al.  Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[108]  K. Takeshige,et al.  1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. , 1990, Biochemical and biophysical research communications.

[109]  S. Przedborski,et al.  The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice , 2006, Proceedings of the National Academy of Sciences.

[110]  D. D. Di Monte,et al.  Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. , 2007, The Journal of biological chemistry.

[111]  J. Poirier,et al.  Superoxide Dismutase Expression in Parkinson's Disease , 1994, Annals of the New York Academy of Sciences.

[112]  R. Ramsay,et al.  Relation of superoxide generation and lipid peroxidation to the inhibition of NADH-Q oxidoreductase by rotenone, piericidin A, and MPP+. , 1992, Biochemical and biophysical research communications.

[113]  G. Perry,et al.  Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[114]  Todd B. Sherer,et al.  Mechanism of Toxicity in Rotenone Models of Parkinson's Disease , 2003, The Journal of Neuroscience.

[115]  M. Block,et al.  Microglia-mediated neurotoxicity: uncovering the molecular mechanisms , 2007, Nature Reviews Neuroscience.

[116]  P. Mcgeer,et al.  Inflammation and neurodegeneration in Parkinson's disease. , 2004, Parkinsonism & related disorders.

[117]  C. Marsden,et al.  Alpha-tocopherol levels in brain are not altered in Parkinson's disease. , 1992, Annals of neurology.

[118]  M. V. Van Woert,et al.  Brain peroxidase and catalase in Parkinson disease. , 1975, Archives of neurology.

[119]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[120]  Yasuto Itoyama,et al.  Systemic Increase of Oxidative Nucleic Acid Damage in Parkinson's Disease and Multiple System Atrophy , 2002, Neurobiology of Disease.

[121]  A. Kupsch,et al.  Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. , 2007, Archives of neurology.

[122]  M. Beal,et al.  Prospects for redox-based therapy in neurodegenerative diseases , 2009, Neurotoxicity Research.

[123]  D. Lynch,et al.  Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. , 2004, The Journal of biological chemistry.

[124]  C. Marsden,et al.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.

[125]  J. Schulz,et al.  Inhibition of Neuronal Nitric Oxide Synthase by 7‐Nitroindazole Protects Against MPTP‐Induced Neurotoxicity in Mice , 1995, Journal of neurochemistry.

[126]  K. Sakumi,et al.  Oxidative damage in nucleic acids and Parkinson's disease , 2007, Journal of neuroscience research.

[127]  K. O’Malley,et al.  The Parkinsonism-inducing Drug 1-Methyl-4-phenylpyridinium Triggers Intracellular Dopamine Oxidation , 2000, The Journal of Biological Chemistry.

[128]  R. Klausner,et al.  The impact of oxidative stress on eukaryotic iron metabolism. , 1996, EXS.

[129]  Takashi Uehara,et al.  Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[130]  J. Trojanowski,et al.  Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by α-, β-, and γ-Synuclein Neuropathology , 2000 .

[131]  M. Oechsner,et al.  Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication , 2004, Neurobiology of Disease.

[132]  G. Zeevalk,et al.  Role for Dopamine in Malonate‐Induced Damage In Vivo in Striatum and In Vitro in Mesencephalic Cultures , 2000, Journal of neurochemistry.

[133]  S. Rhee Cell signaling. H2O2, a necessary evil for cell signaling. , 2006, Science.

[134]  D. D. Di Monte,et al.  Effect of 4-Hydroxy-2-nonenal Modification on α-Synuclein Aggregation* , 2007, Journal of Biological Chemistry.

[135]  C. Shults,et al.  Clinical trials of coenzyme Q10 in neurological disorders , 2005, BioFactors.

[136]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[137]  H. Tohgi,et al.  Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease , 2003, Neuroscience Letters.

[138]  R. Tanzi,et al.  The 5′-untranslated region of Parkinson's disease α-synuclein messengerRNA contains a predicted iron responsive element , 2007, Molecular Psychiatry.

[139]  G. Cha,et al.  Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. , 2005, Gene.

[140]  M. Vila,et al.  Genetic clues to the pathogenesis of Parkinson's disease , 2004, Nature Medicine.

[141]  T. Montine,et al.  Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans , 2002, Neuroscience Letters.

[142]  J. Langston,et al.  Model fusion: The next phase in developing animal models for parkinson’s disease , 2007, Neurotoxicity Research.

[143]  K. Jellinger Lewy body-related α-synucleinopathy in the aged human brain , 2004, Journal of Neural Transmission.

[144]  K. Gwinn‐Hardy Genetics of parkinsonism , 2002, Movement disorders : official journal of the Movement Disorder Society.

[145]  Mark A. Wilson,et al.  The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[146]  R. Burke,et al.  Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[147]  E. Hirsch,et al.  The rotenone model of parkinsonism--the five years inspection. , 2006, Journal of neural transmission. Supplementum.

[148]  C. Marsden,et al.  Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. , 1992, Brain : a journal of neurology.

[149]  P Riederer,et al.  The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease. , 1993, Advances in neurology.

[150]  S. Kish,et al.  Glutathione peroxidase activity in Parkinson's disease brain , 1985, Neuroscience Letters.

[151]  A. Lees,et al.  A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease , 1997, Journal of neurochemistry.

[152]  Wenbo Zhou,et al.  DJ-1 Up-regulates Glutathione Synthesis during Oxidative Stress and Inhibits A53T α-Synuclein Toxicity* , 2005, Journal of Biological Chemistry.

[153]  S. Rhee,et al.  H2O2, a Necessary Evil for Cell Signaling , 2006, Science.

[154]  D. Sulzer,et al.  α-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration , 2006, The Journal of Neuroscience.

[155]  Virginia M. Y. Lee,et al.  Oxidative post‐translational modifications of α‐synuclein in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of Parkinson's disease , 2001, Journal of neurochemistry.

[156]  N. Paricio,et al.  Drosophila DJ-1 mutants are sensitive to oxidative stress and show reduced lifespan and motor deficits. , 2007, Gene.

[157]  David S. Park,et al.  Role of Cdk5-Mediated Phosphorylation of Prx2 in MPTP Toxicity and Parkinson's Disease , 2007, Neuron.

[158]  M. Smith,et al.  Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. , 2007, CNS & neurological disorders drug targets.

[159]  Peter T. Lansbury,et al.  Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.

[160]  J. Troncoso,et al.  S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function , 2004, Science.

[161]  H. Braak,et al.  Nigral and extranigral pathology in Parkinson's disease. , 1995, Journal of neural transmission. Supplementum.

[162]  John Hardy,et al.  The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity , 2000, The Journal of Neuroscience.

[163]  B. Halliwell,et al.  1 Iron toxicity and oxygen radicals , 1989 .

[164]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[165]  Robert W. Taylor,et al.  High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease , 2006, Nature Genetics.

[166]  S J Kish,et al.  Biochemical pathophysiology of Parkinson's disease. , 1987, Advances in neurology.

[167]  Woojin Jeong,et al.  2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications , 2005, Trends in Molecular Medicine.

[168]  M. Smith,et al.  Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease , 1996, Brain Research.

[169]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.